Nov 18, 2009 - Genentech, Inc., a wholly-owned member of the Roche Group, and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
The details can be read here.
No comments:
Post a Comment